Don't wanna be here? Send us removal request.
Statistics
We looked inside some of the posts by pharmanewstrands-blog and here's what we found interesting.
Average Info
Notes Per Post
0
Likes Per Post
0
Reblog Per Post
0
Reply Per Post
0
Time Between Posts
2 days
Number of Posts By Type
Text
17
Last Seen Tumblr Blogs
Fun Fact
The Tumblr office adopted Tommy, an 11-year-old Pomeranian.
Text
Pet Cancer Therapeutics Market Applications, Growth Trends, Key Players
Pet Cancer Therapeutics Market – Efficient Cancer Cure in Companion Animals
Pet cancer therapeutics are the novel drug molecules that exhibit high potential to reduce the effects of cancer, giving access to comprehensive cancer care with minimum side effects. Cancer therapies aims to permanently eradicate the cancerous cells prevalent in pets. The veterinarian recommends specific treatment program such as targeted therapy and combination therapy or chemotherapy depending on the type of cancer, stage, and nature of the cancer.
Request A Sample Copy:
The ongoing research activities undertaken by the scientists for the development of novel formulations and therapies is expected to accelerate the market growth. For instance, the scientists at University of Veterinary Medicine are currently exploring the molecular basis of cancer progression in canine cell lines, stating that the modern cancer therapy can be revolutionized with the introduction of targeted therapies.
The global pet cancer therapeutics market was valued at US$ 183.3 million in 2017 and is expected to witness a robust CAGR of 7.7% over the forecast period (2017 – 2025).
Increasing R&D initiatives for cancer management to augment market growth
Increasing number of research grants to launch various anti-cancer therapies for veterinary cancer treatment is expected to be a major factor driving growth of the global pet cancer therapeutics market in near future. For instance, in 2017, Animal Cancer Foundation (ACF) received a US$ 1 million grant from the Blue Buffalo Foundation to support comparative oncology research, which aimed to study similarities between naturally occurring cancers in people and pets and find effective treatment in both species.
Also, in 2016, the Petco Foundation and Blue Buffalo Foundation invested US$ 2.35 million to support pet cancer research and treatment, as it represents a major cause of illness and premature death in affected species worldwide. Moreover, in 2017, Jackson Laboratory launched Tallwood Canine Cancer Research Initiative (TCCRI), to create a biobank of dog tumors for providing insights on cancer cure through research, in order to develop the most effective cancer therapy. Furthermore, organizations such as Animal Cancer Foundation, Petco Foundation, Veterinary Cancer Society, and PetCure Oncology are conducting oncology research such as canine cancer genome project to understand the genetic makeup of cancer tumors in animals, in order to discover targeted drug therapies with least toxic doses. However, increasing adoption of alternative treatment methods such as herbal medications, homeopathy and adverse effects such as diarrhea, musculoskeletal disorder, anorexia and high cost associated with pet cancer treatment are the factors restraining the market growth.
Increasing incidence and remission rates of pet cancers to accelerate the market growth
Increasing prevalence of cancer indicates a need to adopt approved novel therapies, which are proved to be highly effective for the treatment of cancers in pets, thus, augmenting the pet cancer therapeutics market growth during the forecast period. According to the study by Fetch a Cure, 2015, dogs and cats have a higher incidence of tumors than humans, where dogs are 35 times more likely to develop skin cancer, 4 times more likely to develop breast tumors, and 8 times more likely to develop bone cancer.
According to the study published by Animal Cancer Foundation, 2017, approximately around 25% of all dogs will develop a tumor at some point in their life. Furthermore, increasing number of relapsed cancer rates and the availability of relapsed/ refractory therapeutics integrated with veterinarian recommendation is expected to additionally generate the revenue for the market players.
The duration of remission is less than 15 months in 50% of dog species. In 2017, a novel chemotherapy drug named Tanovea-CA1 (rabacfosadine for injection), manufactured by VedDC, Inc. was conditionally approved by the FDA as a first line treatment for dogs to treat relapsed/refractory lymphoma and canine lymphoma. The conditional approval of drug allows manufacturer to legally sell Tanovea-CA1, before proving it meets the substantial evidence standard of effectiveness for full approval.
The major players operating the global pet cancer therapeutics market include Aratana Therapeutics, Inc., AB Science, Boehinger Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc., VetDC, Inc., Karyopharm Therapeutics, Inc., Regeneus Ltd., Rhizen Pharmaceuticals SA, Oasmia Pharmaceuticals AB, and Zoetis.
Click To Read More On: Pet Cancer Therapeutics Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Dental Implants Market Industry Landscape And Acknowledgement
Dental implants are witnessing steady growth in demand, owing to rise in geriatric population and higher inclination of the populace towards maintaining aesthetic looks. Post the invention of dental implants in1954, the dental implants market revenue has grown manifold and is still highly lucrative for market players. Demand for dental implants is steadily increasing as the procedure offers a perfect solution for artificial teeth surgically imbibed in upper and lower jawbone.
Request A Sample Copy: http://bit.ly/2p4Npla
Cosmetic and dental issues arise as a result of aging. According to National Institute of Dental and Craniofacial Research, geriatric population (aged 65 years and above) have an average of 18.9 remaining teeth, in turn creating a highly lucrative market for dental implants. Technological advancements coupled with high demand for dental implant procedure has resulted in a highly lucrative market characterized by high profit margin for players across the value chain. Advancements in technology allow for implants in people without a proper structured or weak jawbone. In 2015, dental implants accounted for over 15% share of global dental device market revenue.
Dental implants market witnessed a very sluggish growth in terms of innovation post-1957. However, post 2000, many new companies emerged in the market leading to fierce competition among players in a highly fragmented industry. As a result, companies are emphasizing on product innovation to sustain and expand their global market presence. For instance, in 2016, Israel–based Magdent launched a miniature electronic device (MED) capable of accelerating bone growth three times faster than normal. The product is yet to receive approval from the U.S. FDA.
The global dental implants market revenue was valued at US$ 3,619.0 million in 2016 and is expected to expand at a CAGR of 6.3% during 2016 – 2024.
Market Dynamics
With changing market dynamics, companies are emphasizing on product innovation and strengthening of distribution channel to sustain and expand their business reach worldwide. Various macroeconomic factors such as increased geriatric population, growing focus on aesthetics, rise in out-of-pocket spending, and establishment of quality healthcare institutions are expected to bolster sales of dental implant devices worldwide. On an average, over 20% of population in EU is aged over 65 years. Moreover, EU spends nearly 9% of its GDP on healthcare. Increasing consolidation, technological advancement, and company laying emphasis on strengthening distribution channels are some of the key dental implants market trends.
Titanium dental implants segment accounted for the largest revenue in the dental implants market
Among product type, titanium dental implants segment is expected to hold dominant position in the dental implants market over the forecast period. The segment accounted for 44.7% of global market revenue in 2015. However, zirconia dental implants segment is expected to hold dominant position in the market by 2024. Key players are launching mini-titanium dental implants solutions, which are compatible with biologically active drugs that are usually incorporated on the surface of implant to improve osseointegration. The consumers mostly prefer titanium dental implants, as it has longer lifespan.
Zirconia, a corrosion free metal, is one of the newly introduced concepts in dental implants market and the zirconia dental implants segment is expected to register highest CAGR over the forecast period.
Highly competitive Europe market to maintain its dominance throughout the forecast period
Europe is expected to dominate the market throughout the forecast period. The region is expected to account for 30.8% of overall market share by 2024. Competition in dental implants market has increased primarily between Straumann and DENTSPLY Implants.
According to Europa, over 25% of the population in Europe is expected to fall under geriatric age group by 2020. This coupled with high discretionary income in the region is expected to continue to position the region as a highly lucrative market for dental implants. Germany is one of the key markets for dental implants. The country spends highest per capita income on teeth than any other country in Europe.
Asia Pacific, followed by Latin America is expected to register fastest CAGR between 2016 and 2024. Asia Pacific market growth is primarily driven by increasing number of dental implants procedure in China, India, and Japan. India dental implants market is expected to register highest regional CAGR over the forecast period. There are over 5,000 dental laboratories with around 300 dental institutes and 200,000 dentists in India.
Increasing growing consumer base along with better economic growth is expected to create lucrative market opportunity for industry players. In 2015, India imported over 77% of dental implant products from Germany, U.S., Japan, and Italy. The ‘Make in India’ campaign initiated by the Indian government is expected to bolster number of manufacturing facilities across various healthcare verticals including dental manufacturing sites in the country.
Emerging economies to present highly lucrative growth avenues
Dental implant players are focused towards strengthening of direct distribution channel along with partnership with regional manufacturers and distributors. DENTSPLY Implants, Straumann AG, Bicon Dental Implants, Anthogyr, KYOCERA Medical Corporation, Lifecore Dental Implants, Zest Anchors, Implant Innovations Inc, and BioHorizons IPH, Inc.,
Neobiotech USA. Inc., Sweden & Martina, TBR Implants Group, Global D, and MOZO-GRAU, S.A. are some of the key industry players in dental implants market. Straumann AG and DENTSPLY Implants are leading players in Europe. However, there is a wide variation in Europe market, since there is high presence of regional players in Europe. For instance, while TBR Implants Group is a leading France-based dental implants manufacturer, Sweden & Martina holds significant market share in Italy. Nobel Biocare holds significant market share in Asia Pacific, with the company generating around 17% of its regional revenue from Japan.
Click To Read More On: Dental Implants Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Wireless Visual Cortical Stimulator Market Share, Applications, Growth Trends
Market Overview:
Wireless visual cortical stimulator devices are visual prosthetics used to restore functional vision of a blind user It provides electrical stimulator that bypasses defected retinal cells and stimulates viable cells to induce visual perception. On October 26, 2016, Second Sight, announced its first implantation in a 30-year blind patient to provide human proof for the ongoing development of Orion I Visual Cortical Prosthesis (Orion I), wireless visual cortical stimulator. In 2013, the U.S. FDA approved Second Sight’s Argus II System, a visual cortical stimulator that provides electrical stimulation that bypasses defunct retinal cells to stimulate viable cells.
Request A Sample Copy:
The difference between Orion I and Argus II System is that Orion I uses wireless technology. The device allows restoring vision to patients completely blind due to glaucoma, cancer, diabetic retinopathy or trauma cases. The first implantation proved that the device perceive and localize individual light spots with no side effects associated with it.
It is rare that all technological development offers string opportunity, though the first human test of Orion I, wireless visual cortical stimulator proved to be able to treat visually impaired patients with no side effects. The company expects to submit the application to the FDA in early 2017 for the initial completion of clinical trial of the complete system.
Wireless visual cortical stimulator market is segmented on the basis of indication type and end users. On the basis of indication type, the market is segmented into cancer, diabetic retinopathy, trauma, glaucoma, and other indication. Diabetic retinopathy and glaucoma segments are expected to contribute major share to the overall market. ON the basis of end user, the visual cortical stimulator market is segmented into hospital, ambulatory surgical centers, emergency care units, specialized clinics, and others
Increasing Incidence of Diabetic Retinopathy Provides Positive Future Outlook for Wireless Visual Cortical Stimulator Market
The global wireless visual cortical stimulator is expected to witness significant growth in the near future due to increasing number of diabetic retinopathy cases reported worldwide. It is the fifth-most common cause of preventable blindness and moderate to severe visual impairment. In 2010, an estimated 285 million people worldwide suffered from diabetes. The increasing trauma cases and cancer cases are expected to create lucrative growth opportunity for wireless visual cortical stimulator manufacturers and developers.
The growing concern with blindness due to diabetes and governments or organizations initiatives to grow awareness among patients related to blindness treatment through campaigns and national diabetes awareness programs to act as a fuel to the growth of wireless visual cortical stimulator market. In October 2016, Kasturba Heath Society, Mahatma Gandhi Institute of Medical Sciences in India initiated diabetic care program to prevent blindness from diabetic retinopathy aimed to create awareness and prevent blindness from diabetic retinopathy.
The CDC’s Vision Health Initiative (VHI) is one such initiative started by Center for Disease Control and Prevention aimed to create more effective network for vision loss prevention and eye health promotion. The presence of other alternative treatment methods like medication, visual cortical stimulator device will hamper the growth of wireless visual cortical stimulator. The time span for FDA approval and time required for adoption of device is expected to hamper the overall growth of wireless visual cortical stimulator industry. North America and Europe are expected to be major revenue contributors towards the market due to these regions being early adopters of novel technologies.
Click To Read More On: Wireless Visual Cortical Stimulator Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Smart Pills Market - Global Industry Insights, Trends, Size, Share, Outlook
Smart pills can be used to monitor the drug adherence, temperature and some other parameters in the patients. Smart pills are ingestible medical devices that can be taken orally to examine the gastrointestinal tract (GI).The advanced technology of smart pills helps in monitoring of patients, disease diagnosis, and help to improve the drug delivery.
This might help physicians to monitor the patient’s conditions, and to check the timely routine of patient’s medication. The smart pills may alert about the expiry date of medicines, drug completion course and prevent from adverse events. These are expected to replace conventional diagnostic techniques such as endoscopy and colonoscopy. The need for convenient, and accurate treatment strategies has generated the interest in the research of smart pills.
Request A Sample Copy: http://bit.ly/2MCmoQM
The increasing number of gastro-intestinal diseased population to drive the smart pills market
Increasing geriatric population creates a large target group for smart pills manufacturers. This demographic group is highly susceptible to Inflammatory Bowel Disease (IBD). The market has wide scope in the monitoring and diagnosis of the diseases. According to World Health organization (WHO) 50% of people forget to take pills or take wrong medication which will be dangerous for their health, the new smart pills technology is helping in monitoring this conditions.
According to Center for Disease Control and Prevention (CDC), around 1 million people suffered from IBD in the U.S. in 2015. The changing lifestyles, low intake of fibers in the food, stress, food intolerance and allergies are causing the increasing number of gastrointestinal diseases. To cure this disease, conventional methods do not provide accurate results. Need for accurate diagnosis and monitoring for this diseases are some of the major factors driving the smart pills market.
The increasing healthcare awareness and early adoption to novel technologies driving the smart pills market in Europe
Regional segmentation of smart pills market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America and Europe collectively dominate the market. The adoption of these regions for novel technologies which is essential for the smart pills market, new marketing and commercialization strategies, large patient population are some of the causes driving this market in North America and Europe. The Asia Pacific region is one of the growing market however, increasing healthcare awareness, training in endoscope handling, growing predominance of colon cancer and intestinal infections, and major corporate investments in research and development in Japan and other Asian countries would help boost the smart pills market.
The development of novel technologies and partnership between companies helping to boost growth in the smart pills market
The key players operating the smart pills market globally are Boston Scientific Corporation, Olympus Medical Technology, Smart Pill Inc, Medtronic, Philips Healthcare, Given Imaging Ltd and Novartis, Siemens Healthcare, Pentax Medical Company, GE Healthcare, Stryker Corporation.
Click To Read More On: Smart Pills Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Recombinant Vaccines Market Manufacturers, Future Growth Potentials, Key Drivers
Recombinant vaccines are produced using recombinant DNA technology, with the help of a vector. These vaccines stimulate the immune system of an individual and provide immunity against various lethal disease. These vaccines are safe and have less or no side-effects as compared to conventional vaccines, in the prevention of various diseases such as influenza, cholera, typhoid, and dengue. Recombinant vaccines are also used in animals for prevention of diseases such as foot and mouth disease, pneumonia and septicemia, and pox disease.
Vaccination results in the prevention of disease, by producing antibodies against the protein antigen of pathogenic microorganisms. There is increase in the demand for livestock products, which in turn has increased growth of the animal recombinant vaccine segment and Europe dominates the animal recombinant vaccines market as compared to other regions due to highly organized livestock and huge demand of livestock product for the European population. According to Global Agriculture report, there were around 315 million tons of meat produced worldwide in 2014 and expected to increase to 318.8 million tons in 2015.
Request A Sample Copy: http://bit.ly/2o5zk6R
The recent past has witnessed a steady rise in incidence of zoonotic and infectious diseases in humans and animals as well, which lead to the increased research & developments for the innovation of new and effective recombinant vaccines for the prevention of diseases. Government has also taken an initiative to increase awareness regarding vaccination to prevent diseases in community. Manufacturing companies have also started some beneficial programs to provide vaccination free of cost to poor people, which creates a highly conducive environment for growth of the recombinant vaccines market in near future.
National Immunization Program by Queensland Government in Australia and Indradhanush vaccination program in India works to provide vaccination among children throughout the nation. Various organizations such as World Health Organization, World Bank, and United Nations Children’s Funds has also taken and initiative to increase vaccination.
ncrease in the incidence of zoonotic diseases and emerging technologies expected to support the growth of recombinant vaccines market
There is a constant increase in diseases caused by bacteria or virus such as swine flu, malaria, HPV and other diseases, which has raised the demand of vaccination and lead to the eradication of diseases such as polio, and tetanus in few countries. Whit the development in technology there is development in vaccines, which are more effective than conventional vaccines and does not lead to any side effect.
These vaccines are easy to administer in the body orally, intramuscular or intradermal. In the U.S. there were around 212 million malaria cases and 429,000 deaths from malaria is reported in 2015. According to Centers for Disease Control and Prevention report 2017, in the U.S. there were around 49.9% of the children between the ages of 6 months to 17 years received an influenza vaccine.
Continuous investment in research & development for the development of new vaccines and increased awareness and pet adoption are expected to fuel the growth of recombinant vaccines
There are various companies working on the development of vaccine for various disease, which have affected human beings in short span of time such as Ebola, Zika, and H1N1 flu. The companies also working for the development of cancer vaccines different type of cancer includes lung cancer, blood cancer, skin cancer, bladder cancer, brain cancer, kidney cancer, prostate cancer, solid tumors cancer , breast cancer are the target area for recombinant vaccine development, which may expected to support the growth of recombinant vaccine market in the near future. In 2012, according to the World Cancer Research Fund International, globally around 1.7 million new cases of breast cancer are diagnosed. Breast cancers are being targeted in active NCI supported cancer prevention or treatment clinical trials using vaccines.
The vaccine therapy with or without trastuzumab in treating patients with stage IV breast cancer is in phases II clinical trial. The folate receptor alpha peptide vaccine with GM-CSF in patient with triple negative breast cancer trial phase II.
According to National Cancer Institute, in the U.S. there were around 1,685,210 new cases of cancer was reported and 595,690 people died from cancer in 2016. According to American Society for the Prevention of Cruelty to Animals, in the U.S. there were around 3.2 million shelter animals are adopted each year (1.6 million dogs and 1.6 million cats) and adoption of pets are expected to increase, which in turn raise the demand for recombinant vaccines for animals in near future.
Some major key players in the recombinant vaccines market include Merck & Co. Inc., Novartis AG, Protein Science Corporation, GlaxoSmithKline Plc., Green Cross Corporation, Bayer AG, Sanofi S A, Pfizer Inc., and Bharat Biotech.
Click To Read More On: Recombinant Vaccines Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Stem Cell Banking Market Development Industry 2019 Featuring
Stem cells are building blocks of the immune system and blood, and they have the ability to develop into other cell types, in order to help in repairing tissues, organs, blood vessels, and are used in treatment of various disease. The ability of stem cells to regenerate has led to development of various treatments with it, to cure various genetic and auto-immune diseases and disorders.
Stem cells have the potential to transform to any tissue or organ in the body. Stem cells can be found in bone marrow, fetal tissues, baby teeth, fat, human embryos, hair follicles, muscle, and circulating blood, however, cord blood is an effective source of stem cells.
Stem cells from cord blood are preferred due to various advantages such as efficacy in transplant due to less chances of immune rejection during the transfusion. Numerous applications of stem cells such as treatment in various diseases such as cancer, have led to demand for stem cell banking. These stem cells are collected from humans and preserved for the future use.
Request A Sample Copy: http://bit.ly/2mlpYmY
Increasing incidences of chronic disease and the effectiveness of stem cell therapy in the treatment of such diseases is a major driving factor for growth of stem cell banking market. According to the survey by Seattle Children’s Hospital and Research Center, 2013, the survival rate of patient with cancer after stem cell transplant for period of one year was 84% globally. Growing public awareness for stem cell storage is also contributing to stem cell banking market growth.
Additionally, new clinical trial data that supports applications for hematopoietic stem cells from mesenchymal stem cells and cord blood is expected to help in growth of stem cell banking market. Moreover, various organizations are supporting stem cell banking, which is expected to aid in growth of the market. For instance, in 2012, Harvard University and University of Cambridge announced plans to set up a new stem cells research center,decade of storage and this is a major factor driving growth of the market.
Asia Pacific is expected to exhibit significant growth in the global stem cells banking market over the forecast period. This is owing to rising birth rates coupled with increasing prevalence of birth defects, and options of paying for stem banking in monthly instalments, making it accessible to a number of people. For instance, according to the survey by Save the Children India, 2012, India has a booming birth rate of 26 million per year and this is aiding in growth of the market. According to Multicenter Study, 2013, about 10,000 to 15,000 infants are diagnosed suffering from thalassemia and sickle cell anemia in India, indicating high demand for stem cells banking.
However, high cost of stem cell banking is a major hindrance for growth of the market. Stem cell preservation services are expensive and everyone cannot afford it. For instance, according to Meredith Corporation, a private bank generally charges US$ 1,000 to US$ 2,000 to collect cord blood at the time of delivery, with annual storage fees of US$ 100 to US$ 300 each year.
Supportive stem cell research initiatives for personalized medicine to accelerate the market growth
Stem cell banking offers the advantage that it can be readily used, whenever the need for arises, and does not need to be closely matched as bone marrow. According to the Health Research Funding Organization, 2015, children, who received matched cord blood had a 20% higher survival rate than those children who received matched bone marrow. Government organizations are offering support to conduct research and clinical trials for cord blood stem cell.
Therefore, healthcare companies are increasing focusing on investing in research and commercialization of cord blood stem cell therapies thus, augmenting growth of stem cell banking market in the near future. For instance, the International Stem Cell Forum (ISCF) was launched to encourage international collaboration and provide funding for stem cell research. The aim of ISCF was to promote global good practice and accelerate progress in the area of stem cell research.
Major players operating in the global stem cell banking market are Allergan, Plc., Galderma S.A., Integra LifeSciences Corporation, Merz Pharma GmbH & Co. KGaA., Sanofi S.A., SciVision Biotech Inc., Sinclair Pharma Plc., Suneva Medical, Valeant Pharmaceuticals International, Inc., and Anika Therapeutics, Inc. funded by Medical Trust UK and UK Medical Research Council, to conduct research on stem cells and their potential to treat a range of life-threatening conditions. However, low availability of cord blood units, globally and high cost for maintenance are hindering growth of the stem cell banking market.
High therapeutic potential of stem cells for treating genetic diseases is expected to aid in growth of the market
High potential of cord blood and tissues for the treatment of patients with autoimmune diseases is expected to propel the market growth. Moreover, currently available immunosuppressive agents such as steroids, induce long term side effects despite temporary improvements. According to the Health Research Funding, 2015, around 28% of cord blood transplants have been used to treat genetic diseases, with the most common genetic disease treated being severe combined immune deficiency, followed by aplastic anemia.
Stem cells can be stored indefinitely and can easily retain viability even after a decade of storage and this is a major factor driving growth of the market. A study of cord blood stem cells conducted at Indiana University in 2016 demonstrated its viability after 23.5 years of cryogenic storage. Moreover, increasing awareness about stem cell preservation and significance in treating life-threatening diseases has led to increasing demand for of stem cell collection and preservation techniques, thus bolstering the market growth.
Asia Pacific is expected to exhibit significant growth in the global stem cells banking market over the forecast period. This is owing to rising birth rates coupled with increasing prevalence of birth defects, and options of paying for stem banking in monthly instalments, making it accessible to a number of people.
For instance, according to the survey by Save the Children India, 2012, India has a booming birth rate of 26 million per year and this is aiding in growth of the market. According to Multicenter Study, 2013, about 10,000 to 15,000 infants are diagnosed suffering from thalassemia and sickle cell anemia in India, indicating high demand for stem cells banking.
Supportive stem cell research initiatives for personalized medicine to accelerate the market growth.
Stem cell banking offers the advantage that it can be readily used, whenever the need for arises, and does not need to be closely matched as bone marrow. According to the Health Research Funding Organization, 2015, children, who received matched cord blood had a 20% higher survival rate than those children who received matched bone marrow.
Government organizations are offering support to conduct research and clinical trials for cord blood stem cell. Therefore, healthcare companies are increasing focusing on investing in research and commercialization of cord blood stem cell therapies thus, augmenting growth of stem cell banking market in the near future.
For instance, the International Stem Cell Forum (ISCF) was launched to encourage international collaboration and provide funding for stem cell research. The aim of ISCF was to promote global good practice and accelerate progress in the area of stem cell research. Moreover, the UK Stem Cell Bank (UKSCB) provides an international resource for stem cell research by supplying human stem cell lines for the purpose of research and development of stem cell lines for clinical purpose. It also has an active program for research in collaboration with academic institutions.
Major players operating in the global stem cell banking market are Allergan, Plc., Galderma S.A., Integra LifeSciences Corporation, Merz Pharma GmbH & Co. KGaA., Sanofi S.A., SciVision Biotech Inc., Sinclair Pharma Plc., Suneva Medical, Valeant Pharmaceuticals International, Inc., and Anika Therapeutics, Inc.
Click To Read More On: Stem Cell Banking Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Pulse Oximeter Market Outlook and Opportunities in Grooming Regions 2026
Pulse oximeter is a noninvasive device used for monitoring a person’s oxygen saturation. In its most common application mode, a sensor device is placed on thin part of the patient body, which is usually a fingertip or earlobe in adults and in case of infants it is placed across a foot. The pulse oximeter displays the percentage of blood that is loaded with oxygen. Pulse oximeter specifically measures the percentage of hemoglobin, the protein in blood that carries oxygen.
Request A Sample Copy: http://bit.ly/2nzX3vs
Pulse oximeter is particularly convenient for continuous measurement of blood oxygen saturation, noninvasively. Pulse oximeter can be used in any setting where patient’s oxygenation is not stable such as in intensive care, recovery, operating, emergency and hospital ward, pilots in unpressurized aircraft, patient at high altitude for assessment of any patient’s oxygenation, and to determine whether there is need for supplemental oxygen.
Furthermore, the simplicity of use and ability to provide continuous and immediate oxygen saturation values makes pulse oximeters of critical importance in emergency medicine or first aid. Pulse oximeter are useful for patients with cardiac problem, respiratory problems, and chronic obstructive pulmonary diseases.
Pulse oximeters are used for diagnosis of sleeping disorders such as hypopnea and apnea. The pulse oximeter with portable battery is useful for pilots operating in a non-pressurized aircraft where supplemental oxygen is required. Pulse oximeter is also extensively used by mountain climbers and athletes as there is low concentration of oxygen at high altitudes or with extensive workout.
Driving forces for growth of the pulse oximeter market:
High prevalence of diseases that require continuous monitoring is expected to drive growth of the pulse oximeter market. Furthermore, pulse oximeter market growth is also driven by technological advancements in oximeters and increasing adoption of oximeters in critical care, childbirth, neonatal, surgery, anesthesia, and pediatric care. Increasing demand for pulse oximeters is mainly linked to their characteristics such as portability, connectivity, and compact size.
According to the International Journal of Health Policy and Management showed periodic increase during 2004-2012 of aging associated increase in hospitalization, which was pegged at 1.03 million globally. This in turn is expected to favor growth of the pulse oximeter market. Standardization of patient monitoring in clinical practice creates a highly conducive environment for growth of the global pulse oximeter market. According to the National Sleep Foundation, in 2012, around 40 million people in the U.S. suffered from chronic sleep disorder, which is expected to increase use of pulse oximeters.
Regional growth engines of the pulse oximeter market
According to the Centers for Disease Control and Prevention (CDC) and American Academy of Pediatrics (AAP) in September 2014, it is mandatory for critical congenital heart defects (CCHD) screening for newborns. This is expected to boost demand for pulse oximeters in the U.S. and aid the U.S market to retain its dominance throughout the forecast period. Asia Pacific is expected to observe the fastest growth over the forecast period due to increasing investment of industry players in the region. In Europe, increasing number of patients is expected to drive the market growth. According to The European Sleep Apnea Database (ESADA), March 2014, the number of enrollment of patients reached 15,956 along with 5313 follow up visits, which shows that pulse oximeter market is rising in Europe
Major players operating in pulse oximeter market
Major brands in the pulse oximeter market include: The Apple watch – uses pulse oximeter technology for its heart rate monitor. Key players operating in the pulse oximeter market are CAS Medical Systems Inc., Covidien Plc, Masimo Corporation, Nihon-Kohden Corp., Nonin Medical Inc., Opto Circuits Ltd., Criticare Systems Inc., Mediaid Inc., Spacelabs Health care Inc., Philips Healthcare and Welch Allyn Inc.
Click To Read More On: Pulse Oximeter Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Head and Neck Cancer Market Industry 2019-2026
Cancer is the uncontrolled and abnormal growth of cells that results in formation of a mass called tumor. This tumor can be cancerous or benign. Head and neck cancer is the terminology used to define a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses, and mouth. Furthermore, head and neck cancers initiate in squamous cells, cells that line moist surfaces such as those inside the head and neck (for example, the mouth, nose, and throat).
Request A Sample Copy: http://bit.ly/2nl76o4
Salivary glands have different types of cells that can turn cancerous. Chewing tobacco, excessive alcohol consumption, and infection with human papillomavirus (HPV) increases the risk of head and neck cancer. Other risk factors for head and neck cancers include excessive consumption of paan (betel quid), preserved or salted foods, oral health, occupational exposure, radiation exposure, Epstein barr virus infection, and due to hereditary causes.
According to National Center for Biotechnology Information, head and neck cancer is the sixth-most common cancer worldwide, with around 630,000 new patients diagnosed every year, in turn resulting in over 350,000 deaths. Symptoms include a change or hoarseness in the voice, a lump or sore that does not heal, sore throat that does not go away, and unexplained and prolonged trouble swallowing. Around 75% of head and neck cancers are associated with tobacco use, including smokeless tobacco. Infection with HPV is a risk factor for some head and neck cancers.
Head and neck cancer market
On the basis of disease indication, the global head and neck cancer market is classified into:
Laryngeal and Hypopharyngeal Cancer
Nasal Cavity and Paranasal Sinus Cancer
Nasopharyngeal Cancer
Oral and Oropharyngeal Cancer
Salivary Gland Cancer
On the basis of diagnostic methods, the global head and neck cancer market is classified into:
Diagnostic imaging equipment
Endoscopy screening equipment
Bioscopy screening tests
Blood tests
Dental diagnostic
Need for effective and targeted treatment is critical to increase the survival rates
Treatment of head and neck cancer is a major challenge for physicians, as the affectivity and choice of treatment varies from patient to patient and location of the tumor. Owing to complexity of facial structures and functions limits the surgical treatments for head and neck cancers, with surgery being the preferred mode of treatment. Post-surgery, functions such as chewing, talking, and swallowing may be adversely affected. Physicians opt for surgical therapy in combination with radiation therapy for treatment of the malady.
Survival rate of head and neck cancer has reduced from 80% to 50% in last ten years, as currently available treatment options mainly treat the symptoms. Recent developments in the area of advanced chemotherapy and radiotherapy permit preserving some of the functions of the face. The introduction of targeted molecular therapy such as gene therapy, monoclonal antibodies, and antibody drug conjugates creates major growth avenues for the head and neck cancer market.
High incidence rate creates a potential growth opportunity for the market players
Growing occurrence of head and neck cancer and increasing research activities to develop cost-effective treatment options are the factors which are driving growth of the global head and neck cancer market. According to the World Health Organization, 3 - 5% of the population around the globe suffers from head and neck cancer.
Increasing geriatric population and rising number of initiatives by government and non-governmental organizations such as Support for People with Oral and Head and Neck Cancer (SPOHNC) creates a highly conducive environment for growth of the global head and neck cancer market.
Key players operating in the head and neck cancer market are AB Science SA, Bayer AG, Bristol-Myers Squibb Company, Acceleron Pharma, Inc., Astellas Pharma Inc., Boston Biomedical, Inc., AbbVie Inc., and AstraZeneca Plc.
Click To Read More On: Head and Neck Cancer Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Reprocessed Medical Devices Market, Opportunity, Industry Forecast
Reprocessed Medical Devices – Low on Cost, High on Quality
Reprocessed medical devices are used to perform certain validated processes such as disinfection and sterilization that cab be further utilized again. Reprocessing involves three steps that are point of use processing, thorough cleaning and disinfection or sterilization.
Post application of the three steps the devices are tested and remanufactured after appropriate packaging and labelling. Furthermore, such devices usually cost a significantly less as compared to the new device and thus, are widely preferred in cost-sensitive and emerging economies such as India and ASEAN countries.
Request A Sample Copy: http://bit.ly/2lyzzGn
In 2011, as per the United States International Trade Commission (USITC), the U.S is the largest consumer and manufacturer of medical devices and accounts for more than 35.0% of the global market. In the U.S., Original equipment manufacturers (OEMs) holds major share in sales of reprocessed medical devices market. This is mainly attributed to their robust sales and distribution network. Furthermore, as per the USITC some foreign countries such as the U.S., Canada account for a significant percentage of their sales.
For instance, according to Remanufacturing Industries Council, the medical device market in countries such as Italy, India, Brazil, South Korea, Japan, Spain, and Portugal is accounted for 45% of GE Healthcare’s sales of reprocessed medical devices in 2011. Also, for the U.S., European countries are the major suppliers for reprocessed devices, followed by Canada and Mexico.
The global reprocessed medical devices market was valued at US$1,054.6million in2016and is expected to witness a robust CAGR of20.4%during the forecast period (2017 – 2025).
Increased focus on protecting the environment by reducing medical waste being dumped in landfills is significantly contributing to the growth for reprocessed medical devices market
Over 90% of potentially infectious medical waste was incinerated before 1997. In August 1997, the U.S. Environmental Protection Agency (EPA) promulgated regulations creating stringent emission standards for medical waste incinerators due to significant concerns over detrimental air quality affecting human health. EPA’s Office of Air Quality Planning and Standards continues to review and revise the Hospital Medical Infectious Waste Incinerator (HMIWI) standards as required most recently in May of 2013.
The growth in reprocessed medical devices market is also favored by the rise in awareness regarding the adverse environmental effects of dumping medical wastes in landfills. The widespread use of plastics and other non-biodegradable artificial polymers in medical devices is likely to magnify the benefit of this factor to the global reprocessed medical devices market, as the use of biodegradable materials in medical devices has still not been widely incorporated. According to World Health Organization (WHO), every year an estimated 16 billion injections are administered worldwide, but not all of the needles and syringes are properly disposed of afterwards.
Some major key players in the global reprocessed medical devices market include Stryker Corporation, Johnson & Johnson, Vanguard AG), Medline ReNewal , SteriPro Canada, Inc., Pioneer Medical Devices AG, Vascular Solutions, Inc., HYGIA Health Services, Inc., ReNu Medical, Inc., SureTek Medical, Centurion Medical Products Corporation and Vanguard AG.
Click To Read More On: Reprocessed Medical Devices Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Peanut Allergy Vaccine Market Global Market Analysis 2019-2026
Allergies are medical conditions caused primarily by hypersensitivity of the immune system to some external stimulus. Allergy may cause anaphylaxis—a medical condition that can cause irritation of the skin, swelling of throat, shortness of breath, and in some cases, death. Allergies are caused by various allergens such as pollen grains, or certain foods such as peanuts. Vaccination is the process of administering antigenic material or a vaccine to stimulate one’s immune system to build up an adaptive immunity to pathogens.
Food allergy is one of the major forms of allergies. Food allergies can be caused by cow’s milk, eggs, shellfish, and many other foods, including peanuts. However, peanut allergy is very prevalent in the present scenario, especially in children.
Request A Sample Copy: http://bit.ly/2kIeIjx
Therefore, peanut allergy vaccine market is likely to gain significant traction in the near future. Peanut allergy vaccine is administered to patients who are detected with a probability of developing peanut allergy, so as to prevent occurrences of allergy attacks such as anaphylaxis in the future. According to a report published by National Centre for Biotechnology Information, allergy to peanuts as well as tree nuts (TNs) is the principal reason for fatal allergic reactions in the U.S., and the occurrences appear to be rising.
In this 11 year follow up research, over 1% (around 3 million) people reported peanut or tree nut allergies and the condition has been on the rise, mainly amongst children. According to a report by Food Allergy Research and Education (FARE), peanuts caused the most number of allergies in the U.S., among all food allergens. Hence, peanut allergy vaccine market has a major potential for growth in this region during the forecast period (2018–2026).
Government initiative towards creating awareness and regulatory approvals for peanut allergy vaccine is necessary for the growth of the market. Some of the other treatment methods for peanut allergy are oral immunotherapy and epinephrine treatment. However, neither of these treatments has gained significant momentum in the peanut allergy treatment market.
Peanut Allergy Vaccine Market Outlook – Increasing prevalence of peanut allergy and lack of proper treatment
Globally, incidence of peanut allergy is increasing supported by rising birth rate. The risk of peanut allergy is more prevalent in countries such as the U.K., Australia, and the U.S. According to American Academy of Allergy Asthma & Immunology, 30.4% of the children with food allergies suffered from multiple allergy attacks. Peanut allergy is such an epidemic condition in the U.S. that the federal Food Allergen Labeling and Consumer Protection Act (FALCPA) mandated that all packaged food sold in the U.S. that include peanuts as an ingredient have to prominently display the word 'Peanut' on the label. The only solution to peanut allergy is restraining a patient from having peanuts/peanuts containing products.
Nevertheless, peanut vaccine is capable of curing the ailment from a very young age, without any restriction on food. Therefore, the future of the peanut allergy vaccine market is very promising. According to a research published by Asia Pacific Association of Allergy, Asthma and Clinical Immunology, the prevalence of food allergy (or peanut allergy) in Asia is low as compared to the West. Abundant use of peanuts in local cuisines in Asia Pacific is a major factor attributed to low incidence of peanut allergy in the region. As can be inferred from the report, the peanut allergy vaccine market is expected to grow at a considerable rate in the western part of the globe as compared to the eastern part.
Companies operating in the market in the current scenario are focusing on obtaining approval for their products from the respective regulatory bodies. The major companies operating in the market are Allergy Therapeutics, Zicam, Aravax, Immunomic Therapeutic, Inc., Astellas, and Aimmune.
Key Developments
Major market players are involved in different business strategies such as research and development, in order to develop effective vaccine for peanut allergy. For instance, in February 2019, Aravax, an Australia-based biotechnology company, presented positive Phase I data for clinical trial, evaluating safety and tolerability of a novel vaccine ‘PVX108’ at 2019 American Academy of Allergy, Asthma & Immunology (AAAAI). This is an intradermal peanut allergy immunotherapy vaccine.
Major market players are involved in different business strategies such as gaining approval from regulatory authorities, in order to develop effective vaccine for peanut allergy. For instance, in March 2019, Aimmue Therapeutics, Inc., a biopharmaceutical company, received Biologics License Application (BLA) for AR101 from the U.S. Food and Drug Administration (FDA) for review. AR101 is indicated for peanut allergy.
Major market players are involved in different business strategies such as partnership and collaboration, in order to develop effective vaccine for peanut allergy. For instance, Sementis, an Australia-based biotechnology company, collaborated with Ensi Pharama, a U.K.-based company, development and evaluation of peanut allergy vaccine.
Click To Read More On: Peanut Allergy Vaccine Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Measles, Mumps and Rubella (MMR) Vaccines Market Share, Applications, Growth Trends, Key Players
Measles, mumps, and rubella are the three common contagious airborne diseases that are highly caused by virus transmitted by sneezing and coughing of the infected person, which could lead to serious complications or death among children. Vaccines of these diseases are sold as attenuated viral vaccines, manufactured in a lyophilised formulation, which requires reconstitution with water for injection diluent and are available in two forms i.e. monovalent as well as combinational vaccines.
Request A Sample Copy: http://bit.ly/30Ffmgz
Combinational MMR vaccines comprises mixture of two or more viral strains. These measles, mumps, and rubella vaccines are administered by subcutaneous injection to children as well as adults. It is generally administered to children aged 1 year and second dosage can be administered as early as one month after the first dose. According to CDC, two doses of measles, mumps and rubella vaccine are 97% effective against measles and 88% effective against mumps. One dose of measles, mumps, and rubella vaccine is 93% effective against measles, 78% effective against mumps, and 97% effective against rubella.
Currently, few vaccines available in the measles, mumps, and rubella vaccine market are sold under the trade name of M-M-R II, ProQuad, and Attenuvax by Merck Co. Inc.; Varilrix, Priorixtetra and MMR by GSK; Trimovax by Sanofi Pasteur and Tresivac by Serum Institute of India.
Measles, Mumps, and Rubella Vaccine Market Drivers
Vaccine manufacturers are focusing on partnering with organizations such WHO, UNICEF, and GAVI Alliance to improve their vaccination programs, in order to reach the maximum population to offer vaccines. In spite of several governmental initiatives, measles is a leading cause of death among young children. Therefore, increasing success rate of vaccination programmes depends on government initiatives of each country. Some organizations are focusing on initiative, in order to reduce the prevalence of these diseases.
For instance, GAVI Alliances has undertaken an initiative to provide vaccination in high-risk countries such as Afghanistan, Chad, Ethiopia, the Democratic Republic of the Congo, Nigeria and Pakistan. Similarly, in 2017, the Government of India launches Pan-India Measles-Rubella vaccination campaign, under which children ages from 9 months to 15 years are vaccinated to reduce the incidence of these disease in children. Such initiatives by various organizations and governments is expected to aid in growth of the market. Furthermore, development of combinational vaccines could aid in reducing cost and adverse effects by reducing the number of vaccination programme.
The global measles, mumps, and rubella vaccines market is segment on the basis of geography into North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. According to the Pan American Health Organization (PAHO), 2017, measles and rubella have been eliminated from the Americas region, however, the challenge lies in preventing the outbreak. However, according to a report by CDC’s National Center for Immunization and Respiratory Diseases (NCIRD), in 2014, the U.S. recorded 667 number of measles cases from 27 states, which was the highest number of cases since measles elimination was documented in the U.S. in 2000. This states that the vaccine programs were unsuccessful in preventing the outbreak of the disease.
Key manufacturers in the measles, mumps, and rubella vaccine market are focusing on launching new vaccines, in order to enhance their share in the market. According to Access to Medicine Foundation index, 2017, vaccine market is dominated by four major players, collectively referred as 'big four': GSK, Merck & Co., Inc., Pfizer, and Sanofi. Big four contribute to 80% of the global vaccine revenue.
Players vary significantly by portfolio and pipeline size. Three of the four companies have larger pipelines than Merck & Co., Inc. or Pfizer. In March 2107, GSK’s measles, mumps, and rubella vaccine for indication of measles, mumps, and rubella prophylaxis was in phase III trial, which is expected to commercialize in the forecast period of 2017 to 2025. Priorix and Priorix Tetra Measles, mumps and rubella vaccine of GSK are expected to lose their patents in 2019 in the U.S. Some small players such as Daiichi Sankyo and Takeda are focusing on launching vaccines for MMR in regional markets. For instance, Daiichi Sankyo’s VN-0102/JVC-001 is measles, mumps, and rubella vaccine in phase I clinical trials as of May 2016.
Side effects related to vaccinations could be a major factor restraining growth of the measles, mumps, and rubella vaccine market. For instance, in 1998, Japan stopped using trivalent combinational measles, mumps and rubella vaccine due to outbreak of non-viral meningitis and other damaging side effects which will restrict the MMR vaccine market.
Measles, Mumps, and Rubella Vaccine Market - Competitors
The major manufacturers with WHO prequalified measles, mumps, and rubella vaccines are GlaxoSmithKline (Belgium), Merck & Co. Inc. (USA) and Serum Institute of India Ltd, among others.
Click To Read More On: Measles, Mumps, and Rubella Vaccine Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Automated Breast Ultrasound Systems (ABUS) Market Share, Applications, Growth Trends, Key Players
Use of conventional handheld ultrasound systems (HHUS) is time consuming and requires technical skills in analyzing the images. The advent of automated breast ultrasound systems (ABUS) has helped alleviate this issue. In 2015, the U.S. Food & Drug Administration (FDA) approved ABUS for supplemental screening of women with dense breasts. Its usage in preoperative evaluation is also increasing in order to identify the presence and amount of cancer tissues, prior to the surgery. Hence, it is vital for ultrasound system manufacturers to closely monitor the various trends in this highly lucrative market and accordingly align their business strategies in order to capitalize on these opportunities.
Request A Sample Copy: http://bit.ly/2kweV9C
High prevalence and incidence rate of breast cancer is a major factor contributing towards growth of automated breast ultrasound systems market. According to the American Cancer Society, 246,660 new cases of breast cancer would be reported in the U.S. in 2016. Moreover, the risk of breast cancer increases with age. Initiatives by the WHO in collaboration with national governments to promote early detection, diagnosis and treatment is further propelling demand for ABUS for breast screening.
However, high costs associated with installation and training of personnel is constraining market growth. Therefore, companies are adopting strategies such as providing FDA approved on-site training, entering into strategic agreements, and introducing innovations in their existing portfolio in order to enhance their market presence.
ABUS are primarily used for screening purpose in adjunct to mammography
ABUS are approved by the U.S. FDA for screening in conjunction with mammography for dense breasts. Radiologists are inclined towards adoption of ABUS as they provide high quality 3D images. Surgeons are adopting this system for pre-operative evaluation of breast to accurately identify the tumor size and location. HHUS are mainly preferred for preoperative evaluation as compared to ABUS, due to high cost associated with ABUS and lack of skilled radiologists to operate the ABUS system during the crucial preoperative period.
High prevalence of breast cancer and awareness campaigns driving demand for ABUS in developed countries
Factors attributable to the growth of ABUS in North America and European markets include increased patient awareness, high uptake of early breast screening, and availability of funds to install relatively expensive ABUS.
According to the World Health Organization (WHO), 232,924 new cases of breast cancer were diagnosed in 2013. Moreover, the American Cancer Society estimates that until 2016 there are over 2.8 million breast cancer survivors in the U.S.
According to the Cancer Research UK, the incidence rate of breast cancer in the U.K is expected to rise by 2% from 2014 to 2035
Public Health England launched a campaign called ‘Be Clear on Cancer’ (2015) to raise breast cancer awareness among women over 70 years. Moreover, research and development in the field is encouraged through the Breast Cancer Now Catalyst Programme (2016).
High prevalence coupled with government awareness drives are driving demand for ABUS in the U.S. and U.K.
Increasing awareness programs related to breast cancer driving demand in Asia-Pacific region
Asia-Pacific possess immense revenue potential for the growth of ABUS market. Demand for ABUS in Asia-Pacific in terms of volume is expected to increase at a CAGR of 24.4% during 2016 – 2024. Lack of awareness had deterred the uptake of early breast screening until various cognizance initiatives were undertaken by ABUS manufacturers and non-profit and regional cancer organizations. Some noteworthy initiatives include The Pink Initiative organization in India, Breast Cancer Initiative East Africa Inc. and Pink Ribbon Breakfast initiative by Cancer Australia. Moreover, denser breast tissues in the Chinese population is driving demand for ABUS in China at a rapid pace.
Automated breast ultrasound systems manufacturers are following inorganic strategies to increase their footprint
Inorganic growth roadmap is the key strategy followed by market leaders. For instance, GE Healthcare acquired U-Systems, Inc. in 2014 to expand their breast care innovations portfolio. Philips partnered with SonoCine, Inc. in 2014 to provide ABUS imaging for its ultrasound systems. Hitachi Aloka Medical America, Inc.
entered into a strategic alliance with iVu Imaging Corporation in 2014, gaining exclusive distribution rights for iVu’s SOFIA (ABUS) system in North America. This agreement helped iVu Imaging Corporation to get access to the expanded channel and also helped both the companies to leverage the technical expertise of the other which further improved the performance of SOFIA.
Click To Read More On: Automated Breast Ultrasound Systems (ABUS) Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Regenerative Artificial Skin Market Industry Landscape And Acknowledgement and Opportunity Analysis, 2018-2026
Regenerative Artificial Skin Market
Incidence of accidental skin burns are increasing across the globe. Life threatening skin injuries, traumas, and burns require immediate surgical procedure to restore skin and avoid future complications. Skin burns are broadly classified into three levels, namely 1st, 2nd, and 3rd degree burns. In third degree of burns where there is little or no intact skin, artificial skin graft is the most useful treatment option. Artificial skin covers and protects the wound and also promotes regeneration of natural skin.
Request A Sample Copy: http://bit.ly/2kTcrSL
Artificial skin is usually prepared from collagen, which is easily resorbed by the body and facilitates generation of new skin on the affected area. According to the American Burn Association, 486,000 people received medical treatment for minor burns and 70,000 people were hospitalized for severe skin burn requiring acute care in the U.S, in 2015. Various players in the market are carrying R&D activities to develop new technology related to artificial skin regeneration. One such instance is an autologous spray on skin, Recell, by Avita Medical.
Artificial Skin Treatments
Various skin repair devices are available, which are used to heal the affected part. These include Dermagraft, OrCel, Integra, Biobrane, Apligraft, Matriderm, Hyalomatrix, Renoskin, and Composite Cultured Skin. Dermagraft is used to help in wound closure of diabetic foot ulcers. Orcel is used to cover and aid in wound healing. Composite Cultured Skin also contains living cells and is specifically used in children with recessive dystrophic epidermolysis bullosa. Integra is used for treatment of severe burns.
Inadequate Medical Infrastructure and Low Access to Medical Facilities in Developing Economies a Major Restrain for Market Growth
The market for regenerative artificial skin is growing in the U.S., mainly driven by increasing number of patients with skin diseases. According to Skin Cancer Foundation, each year over 5.4 million cases of non-melanoma skin cancer are reported and over 3.3 million people are treated for the same in the U.S. Also, there are more new cases of skin cancer reported than the combined incidence of cancers of the breast, prostate, lung, and colon each year. Regenerative artificial skin market in Europe is growing due to skin disease being a very pertinent issue in the region. Robust medical infrastructure, presence of global players, and advancements in technology also contribute to market growth of the regenerative artificial skin in the region. In Asia, the market for regenerative artificial skin is projected to grow in the near future due to increasing number of people opting for skin treatment procedures.
Lack of Essential Sterile Environment Restricts Access to Regenerative Artificial Skin
Regenerative artificial skin market is expected to grow, with increasing incidence of burns. In addition, rising prevalence of skin diseases, growing number of harmful acid accidents, and increasing number of major body surgeries conducted is projected to positively impact regenerative artificial skin market in the near future. However, issues with acceptance by the recipient body and lack of sterile product and nutritional supply to regain the natural structure restricts growth of regenerative artificial skin market, especially in developing regions.
Rapid Advancements in Technology
Researchers and biotechnicians at the U.S army institute of surgical research are developing artificial skin that can be stored in a spray bottle and would regenerate and grow as applied on the body. This new technology would be of great aid in emergency situations, especially for military personnel during war situations. Furthermore, several companies in the market place are increasing their product portfolio related to regenerative artificial skin market. Some of the key players in the global regenerative artificial skin market are Integra Life Sciences Corporation, Mylan N.V., Johnson & Johnson Services, Inc. Smith & Nephew and Mallinckrodt plc.
Key Developments
Increasing research and development activities, as well as product innovations by market players are some of the key factors driving the market growth. For instance, in April 2019, South Korea-based T&R Biofab registered a patent for its 3D bioprinting technology to create artificial skin. TEmail:[email protected] he technology operates through the 3D printing of dermal and epidermal cells that uses a porous 3D structure to form skin with similar characteristics to actual tissue.
Strategic acquisitions and partnerships among key players are expected to drive the market growth. In May 2019, Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices entered an agreement to acquire Solsys Medical, LLC, and a regenerative medical company. The acquisition is expected to help Misonix to expand its portfolio with the addition of Solsys Medical’s wound care solutions.
Click To Read More On: Regenerative Artificial Skin Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Ovarian Cancer Drugs Market Pipeline Analysis 2018
Ovarian cancer is one of the most dreadful type of cancer widely found in women. In this cancer, abnormal cells growth is experienced in the ovaries, which has potential to invade or adversely affect other body parts such as abdomen layers, lining of the bowel and bladder, lymph nodes, and liver. Initial stages of ovarian cancer are associated with few vague symptoms, which further manifest as the cancer grows. These symptoms include inflating, pelvic ache, abdominal puffiness, and loss of appetite.
Request A Sample Copy: http://bit.ly/2mk94EF
Ovarian cancer is a relatively rare cancer as compared to other types, though risk is higher among women who have ovulated more over their lifetime, which can also include females who have never borne a child and those who began ovulating at a very young age. According to American Cancer Society, around 10% of ovarian cancer cases are related to inherited genetic risk. Women with mutations in BRCA1 or BRCA2 genes have 50% chance of developing breast or ovarian cancer. Ovarian carcinoma, is the most common ovarian cancer that accounts for 95% of cases, globally.
Ovarian cancer drugs market supported by growing aging population in the U.S. and U.K.
Rising number of ovarian cancer cases recorded over the recent past, is creating a highly conducive environment for growth of the ovarian cancer drugs market. According to American Cancer Society, in 2016, around 22,280 new cases of ovarian cancer were diagnosed, leading to 14,240 deaths in the U.S. According to the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute data, an increase in all new cancer cases is recorded, with ovarian cancer accounting for 1.3% of the incidence rate, and 2.4% of all related deaths, in 2016. The number of new ovarian cancer cases account for 11.9 per 100,000 women, and the total deaths account for 7.5 per 100,000 women, annually.
According to World Cancer Research Fund International data on the basis of highest rate of ovarian cancer by country: Fiji, age standardized rate per 100,000 is 14.9, followed by Latvia and Bulgaria with age standardized rate per 100,000 being 14.2 and 14.0, respectively. The U.K. stands tenth, with age standardized rate per 100,000 pegged at 11.7. Around 58% of ovarian cancer cases are diagnosed in emerging economies, with the highest incidence rate recorded in Africa and Asia Pacific. In the U.K., around 46% of women diagnosed with ovarian cancer, survive for around five years or more following the onset of the disease. According to Australian Government, Cancer Australia, as of 2017, 1,580 new ovarian cancer cases are estimated to be diagnosed, accounting for 2.5% of ovarian cancer cases among all new cancer cases in the country. This is estimated to result in 1,047 deaths in 2017. Thus, the ovarian cancer drugs industry is expected to gain significant traction in developed regions, in the near future.
Current scenario in ovarian cancer drugs market: High prevalence of ovarian cancer among women over 60 years in the U.S. and U.K.
Regional segmentation of the global ovarian cancer drugs market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America accounts for the largest market share, mainly due to presence of major players and adoption of advanced medical technologies in countries such as the U.S. and Canada.
According to American Cancer Society, most of the ovarian cancer cases are reported among women aged 60 years and above. According to Cancer Research UK, in 2014, 7,378 new cases of ovarian cancer were reported in the country, of which around 53% of cases diagnosed were among females aged 65 years and above.
Combinational drug approach, a novel approach in the ovarian cancer drugs market
Key players operating in the ovarian cancer drugs market include Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Novogen, Inc., Genentech Inc., Aetera Zenteris Inc., Boehringer Ingelheim GmbH, and F. Hoffman-La Roche Ltd. Major companies in this market are constantly working towards introducing innovative products and lowering production costs in order to enhance profitability. For instance, Roche’s blockbuster drug Avastin (bevacizumab) used in combination with carboplatin and paclitaxel is being used to treat ovarian cancer.
Key Developments
Research and development related to the diagnosis and treatment of ovarian cancer is expected to offer lucrative opportunities for market players. For instance, in August 2019, researchers from The George Washington University School of Medicine and Health Sciences, U.S. identified ovarian cancer drug resistance protein that needs to be blocked for the treatment of patients with platinum-resistant ovarian cancer.
Click To Read More On: Ovarian Cancer Drugs Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Custom LASIK Surgery Market Key Players, Trends, Emerging Growth Factors and Regional Forecasts to 2024
custom LASIK surgery market has grown manifold over the last decade. Increasing demand for minimally invasive therapy along with rise in prevalence rate of refractive disorders has boosted overall demand for LASIK surgery procedure in recent years. Most of the LASIK surgery procedure has been carried out for treatment of patients suffering from myopia.The ophthalmic industry has huge un-met potential. Expected commercialization of FDA-approved LASIK surgery systems is expected to fuel overall custom LASIK surgery market growth during the forecast period (2016–2024
Request A Sample Copy: http://bit.ly/2mqgxlR
Changing lifestyle patterns has in turn led to weakening immunity and has inadvertently increased susceptibility to various health problems worldwide. The global chronic disease incidence rate has increased significantly over the last two decades. Eye related diseases have also increased in the recent past. Over 150 million people in the U.S. wear corrective eye wear according to the American Academy of Ophthalmology 2016 statistics. Myopia is the widely prevalent eye-disorder and its prevalence rate is highest in Japan. High demand for effective treatment approach has led to increased demand for custom LASIK surgery procedure worldwide.
Companies engaged in custom LASIK surgery market are expected to generate significant return on investment (ROI) over the forecast period. The technology has clear added advantage over the conventional approach. While conventional eye exams detects only two corneal abnormalities (spherical and cylindrical), wavefront-guided LASIK system detects infinite number of abnormalities. Moreover, only 1-3% of patients experience LASIK eye surgery complications, making it a highly preferred technique for eye surgeries in the present scenario.
Wavefront guided has emerged as the highest revenue contributor among procedure segments
Wavefront guided procedure segment is expected to dominate the custom LASIK surgery market procedure throughout the forecast period. The segment has been estimated to account for 45.8% share of the global custom LASIK surgery market revenue in 2016. This procedure involves detailed wavefront generated measurements of light traversing through the eyes. The procedure helps in offering personalized treatment to patients based on the unique anatomy of the patient’s eye. It is highly precise and more specific compared to conventional LASIK surgery.
WaveScan System CustomVue LASIK (Abbott Medical Optics), Technolas 217z Zyoptix System for Personalized Vision Correction (Bausch + Lomb) and iDesign Advanced CustomVue LASIK System (Abbott Medical Optics) are some of the FDA-approved wavefront guided custom LASIK systems.
WaveLight Allegretto Wave Eye-Q Excimer Laser System (Alcon) is a FDA approved wavefront-optimized LASIK systems.
Topography-guided LASIK systems have gained significant traction in the last few years. Contoura Vision with the WaveLight Allegretto Wave Eye-Q Excimer Laser System is one such example of FDA approved topography-guided LASIK system.
Rapid increase in demand for custom LASIK surgery procedure in the emerging economies to boost market growth
North America, followed by Europe accounted for major share of global custom LASIK surgery market revenue in 2016. These two regions are together estimated to account for 65.1% of overall market revenue. However, the market for LASIK surgery procedure in Asia Pacific is projected to surpass that in in Europe by 2019.
The primary factor for market growth in Asia Pacific is increased installations of LASIK systems in eye-care facilities in Japan. Japan is projected to account for 51% share of the custom Asia Pacific LASIK surgery market in 2017. Increasing patient awareness, high disposable income and improvement in the healthcare infrastructure has resulted in rise in number of LASIK surgeries and in turn, is resulting in growth of the custom LASIK surgery market in the country.
Multinational players need to tap into potential addressable market in emerging economies
Product portfolio expansion and partnerships with local players are key custom LASIK surgery market trends, which are expected to shape the industry in the near future.Moreover, companies are focusing on receiving regulatory approval for their products to differentiate their product offerings. For instance, Abbott received FDA approval for iDesign Advanced WaveScan Studio in 2015. Major players in the global custom LASIK surgery market include Alcon Laboratories, Inc., Bausch & Lomb, Carl Zeiss, Inc., Abbott Medical Optics, Nidek, Inc., and Technolas Perfect Vision GmbH.
Click To Read More On: Custom LASIK Surgery Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Opioid Induced Side Effects Treatment Market Global Market Analysis 2018-2026
Opioids are the class of drug that include strong pain relievers and illegal drugs such as heroin and illicit pain relievers for example hydrocodone, oxycodone, morphine and fentanyl. Also they are available legally on prescription. These drugs interact with opioid receptors on nerve cells in body and are well known for the management of acute pain and cancer related pain among patients of all age group.
However, opioid drugs use in noncancerous patients is contentious, mostly related with chronic pain treatment and the major reason behind it the psychological addiction which may occur due to the continuous use of opioid drugs also other side effects may induce due to use of opioid drugs are nausea, sedation, constipation, dizziness, vomiting, sweating, headache, respiratory depression and physical dependence, among these constipation is the mostly observed problem occurs in 40% to 95% of patients treated with opioid. Also, some side effects such as delirium and drowsiness depends on dose and they can be avoided by reducing the amount of dose.
Request A Sample Copy: http://bit.ly/2kQSGeC
As per stats published by National Institute on Drug Abuse (NIDA) on February 2017, despite decreased use of cocaine after 2010, deaths related to cocaine overdose increased, this increase was associated with opioids, primarily with synthetic opioids. Furthermore, according to NIDA, in 2013, the number of prescriptions for opioids was 207 million around the globe with major share accounted by North America and in 2012, around 2.1 million people in the U.S. suffering from disorders related to prescription opioid pain relievers and out of that, around 467,000 people get addicted to heroin. This fact in turn is expected to favor the growth of opioid induced side effects treatment market in the near future.
Opioid induced side effects treatment market is expected to gain rise in market revenue in the near future on the basis of the fact that according to United Nations Office on Drugs and Crime (UNODC) in 2010, annual prevalence of opioids was around 0.6-0.8% in the people having age group 15-64 and 0.3-0.5% in the people having age more than 64 years.
Centers for Disease Control and Prevention (CDC) says that in 2015, in U.S. more than 15,000 people died because of overdose of opioids and highest overdose rate observed in the people between age group of 25-54 years. Furthermore, around 2 million people were dependent on prescription opioids in 2014 and prescription opioid receiver for noncancerous pain were 1 in 4 which takes these drugs for addiction. Also, in the U.S. every day, more than 1000 people treated in emergency department due to misuse of prescription opioids.
The side effects induced due to opioids can be avoided by, modifying the dosage of opioids, altering the route of administration, by changing the dosing interval, altering the opioid drugs and by replacing the opioids by certain antidepressants and anticonvulsants.
Increase in prevalence of chronic disease and cancer cases with raised use of prescription based opioids will favor the growth of opioid induced side effects treatment market in the near future
North America accounts for the major market share of opioid induced side effects treatment market, as U.S. is the biggest consumer for prescription based opioids. As per NIDA in 2013, out of the globe U.S. accounted around 100 percent in case of hydrocodone for example – Lortab, Norco and Vicodin, and 81% for oxycodone for example Endocet and Percocet. Also, as per American Society of Addiction Medicine (ASAM), drug overdose is the leading cause of death in U.S. and prescription opioids is the leading factor behind it. In 2015, 12,990 deaths were related with prescription based pain relievers.
The growth in opioid induced side effects treatment market is expected high in North America followed by Europe and APAC region. As per the data published by UNODC in 2012, the APAC and Africa region are the emerging markets for raw opium which could feed to increase opioid consumption and support the growth of opioid induced side effects treatment industry in near the future. Furthermore, only 20% of opioid users received treatment against their drug dependence and treatment demand is growing in Asia and Europe region. The South America has shown negligible growth in demand for treatment against opioid drug dependency.
As very few percentage of opioid users received treatment and more are looking for the treatment options in emerging economies as well as in developed region provides scope for the companies to develop and make available the treatment against opioid induced side effects. This in turn is projected to favor the gain in traction for opioid induced side effects treatment market.
Some major medications in opioid induced side-effects treatment market are risperidone, methylphenidate, cetirizine, fexofenadine. In 2014, Naloxone hydrochloride injection (Evzio), a prescription treatment against opioid overdose side effects received approval by U.S. Food and Drug Administration (FDA). It is the first auto-injector designed to use outside of the health care setting which can be used by care taker to treat person have had overdose of opioids.
Some of the key players in the global opioid induced side effects treatment market are Shionogi & Co., Ltd., Cubist Pharmaceuticals, Inc., AIKO Biotechnology, Inc., SLA Pharma AG, Progenics Pharmaceuticals Inc. and AstraZeneca plc.
Click To Read More On: Opioid Induced Side Effects Treatment Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Dental Equipment Market Pipeline Analysis 2018
Practice of dentists has shifted from being focused on disease treatment to preventive measures. This change in market dynamics is acting as a catalyst for development of new technologies for diagnosis and treatment of dental issues Growing awareness about dental care among consumers has translated into rising number of routine-check-ups and growing spending on maintaining oral health. This is in turn spurring demand for dental care equipment, including dental lasers, imaging systems, and computer-aided design and computer-aided manufacturing (CAD/CAM) systems.
Request A Sample Copy: http://bit.ly/2lV30SY
Dental equipment finds extensive application in diagnosis and treatment of dental disorders such as dental cavities, gingival disease, and periodontal (gum) disease. Advent of 3D printing in dental industry creates a highly favorable environment conducive for market growth and helps dentists provide better services through use of highly efficient diagnostic and treatment tools. Moreover, growing public awareness about dental treatment options, coupled with increasing expenditure on dental care is driving patients to opt for preventive measures.
According to a study published in the American Dental Association’s research paper of 2014, around 52.3% of adults in the U.S. visited a dentist every six months. Focus on enhancing patient’s experience through high-quality treatment outcomes is driving demand for dental equipment worldwide.
Development of CAD/CAM & 3D printing is expected to drive dental equipment market growth
Incision during surgeries can be carried out precisely by using laser and electro surgery techniques. This will reduce the damage caused to tissues and will aid in faster healing. The time taken for prosthodontic restoration procedures has reduced to one day due to the development of CAD/CAM. By replacing conventional radiology equipment with digital radiology equipment equipped with picture archiving and communication systems (PACS), treatment records can be archived. Moreover, outcomes of dental treatments have improved due to 3D printing technology. When compared to the conventional CT systems, cone beam CT systems provides clear extra oral images and exposure to harmful X-rays will be minimal.
High treatment costs in developed economies fueling influx of dental tourists in emerging economies
According to the New National Survey published in the American Dental Association in 2014, 40.2% of adults in the U.S. indicated that they would forego dental care due to high costs associated with it. According to 2016 statistics of the Oral Health Foundation, 88% of adults in the U.K.do not have dental insurance and around 63% of adults prefer visiting National Health Service (NHS) dentists rather than private dentists due to high costs associated with the later.
High dental cost involved in cosmetic dentistry dental caries, periodontal disease treatment and overall dental care in developed economies is fueling growth of dental tourism in emerging regions such as Asia, Latin America, and Eastern Europe. Rapid development of dental tourism hubs such as India and Brazil would spur growth of the dental equipment market in emerging regions.
Increasing preference for refurbished dental equipment impacting the growth of overall dental equipment market
Budget constraints in emerging countries such as India, China, Brazil and Eastern European countries is driving demand for refurbished dental equipment. This aids the newly established dental clinics and laboratories to achieve cost-efficiency with quality throughput. New dental equipment such as cone beam CT systems, vacuums & compressors, cad/cam, digital X-ray units and laboratory equipment involve high capital investment.
This may increase the cost of patient dental procedures, thus negatively impacting the number of patient visits. Therefore, most dentists and hospitals in emerging countries prefer refurbished equipment, which in turn helps them pass on the cost-saving benefits to their patients. Market players such as Danaher Corporation, Planmeca Oy, and Dentsply Sirona, Inc. must consider the cost parameters while targeting the cost-sensitive customer base in emerging countries that are projected to be highly lucrative dental equipment markets in the near future.
Click To Read More On: Dental Equipment Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes